Narwhal Capital Management Sells 12,071 Shares of Pfizer Inc. (NYSE:PFE)

Narwhal Capital Management reduced its stake in Pfizer Inc. (NYSE:PFE) by 58.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 8,474 shares of the biopharmaceutical company’s stock after selling 12,071 shares during the period. Narwhal Capital Management’s holdings in Pfizer were worth $225,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of PFE. Empirical Financial Services LLC d.b.a. Empirical Wealth Management raised its position in shares of Pfizer by 7.0% in the 4th quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 46,758 shares of the biopharmaceutical company’s stock worth $1,240,000 after acquiring an additional 3,078 shares in the last quarter. Regatta Capital Group LLC grew its stake in Pfizer by 10.5% in the fourth quarter. Regatta Capital Group LLC now owns 15,594 shares of the biopharmaceutical company’s stock worth $414,000 after purchasing an additional 1,480 shares during the period. Novare Capital Management LLC bought a new position in Pfizer in the fourth quarter worth $228,000. Duncan Williams Asset Management LLC lifted its position in Pfizer by 39.4% during the fourth quarter. Duncan Williams Asset Management LLC now owns 15,623 shares of the biopharmaceutical company’s stock valued at $414,000 after buying an additional 4,416 shares during the period. Finally, AlphaMark Advisors LLC boosted its holdings in shares of Pfizer by 450.1% during the 4th quarter. AlphaMark Advisors LLC now owns 10,468 shares of the biopharmaceutical company’s stock valued at $278,000 after buying an additional 8,565 shares in the last quarter. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Pfizer

In other Pfizer news, Director Scott Gottlieb acquired 1,000 shares of the stock in a transaction dated Wednesday, October 30th. The shares were purchased at an average price of $28.24 per share, for a total transaction of $28,240.00. Following the purchase, the director now directly owns 10,000 shares of the company’s stock, valued at approximately $282,400. This trade represents a 11.11 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 0.06% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on PFE shares. UBS Group decreased their price target on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a research note on Wednesday, January 8th. StockNews.com downgraded shares of Pfizer from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, November 20th. Cantor Fitzgerald reissued an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a research report on Wednesday, October 23rd. Evercore ISI raised Pfizer to a “strong-buy” rating in a research report on Wednesday, October 30th. Finally, Sanford C. Bernstein initiated coverage on Pfizer in a research note on Thursday, October 17th. They set a “market perform” rating and a $32.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating, six have given a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $32.00.

Pfizer Price Performance

NYSE PFE opened at $26.10 on Monday. Pfizer Inc. has a one year low of $24.48 and a one year high of $31.54. The stock has a 50-day moving average of $26.11 and a 200 day moving average of $27.94. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The company has a market capitalization of $147.89 billion, a price-to-earnings ratio of 35.27, a PEG ratio of 0.64 and a beta of 0.64.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 EPS for the quarter, topping analysts’ consensus estimates of $0.64 by $0.42. The firm had revenue of $17.70 billion during the quarter, compared to analyst estimates of $14.92 billion. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The business’s revenue for the quarter was up 31.2% on a year-over-year basis. During the same period in the previous year, the business posted ($0.17) earnings per share. On average, sell-side analysts forecast that Pfizer Inc. will post 2.94 EPS for the current year.

Pfizer Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, January 24th will be issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 6.59%. This is a boost from Pfizer’s previous quarterly dividend of $0.42. The ex-dividend date is Friday, January 24th. Pfizer’s dividend payout ratio is presently 227.03%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.